title: Intravitreous bevacizumab and blood pressure: does 'safe' mean 'safe enough'?
authors.forename: Focke
authors.initials: F
authors.lastname: Ziemssen
authors.forename: Gunnar
authors.initials: G
authors.lastname: Folprecht
authors.forename: Tjalf
authors.initials: T
authors.lastname: Ziemssen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001794:Blood Pressure / Q000187:drug effects*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab